Communication Address:
Solara Active Pharma Sciences Limited
TICEL BIO PARK., 6th floor
Module No. 601, 602, 603, Phase II – CSIR Road,
Taramani, Chennai, Tamil Nadu – 600113.
Tel: +91 44 47406200
Fax: +91 44 47406190
E-mail: investors@solara.co.in
www.solara.co.in

May 10, 2025

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540, 890202

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: SOLARA, SOLARAPP

Dear Sir / Madam,

Subject: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

"Solara Ambernath facility completes USFDA Inspection with Zero 483 inspectional observations".

This is for your information and records.

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited

SUDDAPALLI MURALIKRISHNA
Digitally signed by SUDDAPALLI MURALIKRISHNA
Date: 2025.05.10 09:16:48 +05'30'

S. Murali Krishna
Company Secretary & Compliance Officer
Membership No.: A13372

Encl.: Press release

PRESS **RELEASE**

WWW.SOLARA.CO.IN | BSE:541540 NSE: SOLARA BLOOMBERG: SOLARA: IN | SECTOR: PHARMACEUTICALS

USFDA concludes inspection at Solara's Ambernath Facility with Zero 483 inspectional observations.

Chennai, India – May 10, 2025: Solara Active Pharma Sciences Limited (Solara), a leading pure play Active Pharmaceutical Ingredient provider is pleased to announce that its multi-product manufacturing facility at Ambernath, Maharashtra has completed successfully the inspection carried out by the US Food and Drug Administration (US FDA). The inspection established that the site is in an **"Acceptable State of Compliance" with Zero Form 483 inspectional observations from US FDA.** The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.

Solara continues to stay focused on maintaining the highest level of compliance across its manufacturing facilities.

Commenting on the Inspection Outcome, Sandeep Rao, MD & CEO said "We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy. We stay committed to exhibit the highest level of compliance and constant focus on world-class quality with the validated quality systems established across Solara's manufacturing network."

The Ambernath multi-product API manufacturing facility was established in the year 2004 and is equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, EDQM, WHO, PMDA, and KFDA,

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, Solara offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services. Its API facilities are approved by various international regulatory agencies including the USFDA, EDQM, MFDS, WHO, PMDA etc.

Investor / Analyst contact

Abhishek Singhal
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S
Raghavan. V
✉ investors@solara.co.in

Disclaimer: Certain statements in this document are not historical facts and are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Solara Active Pharma Sciences Ltd will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.